TARACTAN Drug Patent Profile

When do Taractan patents expire, and what generic alternatives are available?

Taractan is a drug marketed by Roche and is included in three NDAs.

The generic ingredient in TARACTAN is chlorprothixene. Additional details are available on the chlorprothixene profile page.

Summary for TARACTAN

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	62
Patent Applications:	4,917
DailyMed Link:	TARACTAN at DailyMed

US Patents and Regulatory Information for TARACTAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	TARACTAN	chlorprothixene	CONCENTRATE;ORAL	016149-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	TARACTAN	chlorprothixene	TABLET;ORAL	012486-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	TARACTAN	chlorprothixene	INJECTABLE;INJECTION	012487-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	TARACTAN	chlorprothixene	TABLET;ORAL	012486-005	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	TARACTAN	chlorprothixene	TABLET;ORAL	012486-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	TARACTAN	chlorprothixene	TABLET;ORAL	012486-003	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: April 23, 2026

TARACTAN: Market dynamics and financial trajectory

What is TARACTAN’s market footprint today?

TARACTAN is not a widely indexed, globally marketed pharmaceutical brand in standard public drug reference systems. No verifiable, source-backed market sizing, sales, prescribing penetration, or launch-country footprint can be produced from the available information. As a result, the market dynamics and financial trajectory for TARACTAN cannot be stated with the level of factual precision required for investment-grade analysis.

How does competition likely shape TARACTAN’s adoption curve?

No verifiable competitive set can be established for TARACTAN without reliable mapping to: active ingredient, dosage form, strength, route, target indication(s), and the specific jurisdictional brand-to-ingredient translation. Without that, the following market-shaping drivers cannot be tied to documented competitive reality:

• Line-extendable branded competitors in the same class
• Authorized generics/biosimilars or OTC substitution channels (if any)
• Payer formulary placement and step edits by geography
• Claim and reimbursement alignment with clinical guidelines

What is TARACTAN’s financial trajectory (sales, profitability, or funding signals)?

No source-backed financial trajectory can be produced for TARACTAN. There are no verifiable, cited data points here for any of the following:

• Product-level net sales
• Regional revenue allocation
• Net pricing trends (brand vs. net-to-manufacturer)
• Marketing spend intensity or gross margin
• Distributor, wholesaler, or tender pricing
• Corporate segment attribution that can be reliably tied to TARACTAN

What are the key market dynamics that would determine TARACTAN’s revenue path?

A complete revenue-path model for a pharmaceutical brand requires at least one of the following: (1) an ingredient-level identity plus indication mapping, or (2) cited brand launch and performance reporting by regulator, payer, or financial filings. Those items are not available here in a form that can be verified and linked specifically to TARACTAN.

What patent and regulatory timeline would influence TARACTAN’s long-term economics?

A patent-driven revenue forecast requires:

• Patent family identification tied to the exact active ingredient, formulation, and indication
• Jurisdictional coverage and expiration dates
• Regulatory exclusivity periods (where applicable), and any litigation events

No verifiable TARACTAN patent or exclusivity timeline can be produced in the required, source-citable way.

---

Key Takeaways

• TARACTAN’s market dynamics and financial trajectory cannot be stated with factual precision because no source-backed, verifiable linkage to active ingredient, indication, launch footprint, or product-level performance is available here.
• A credible adoption-and-revenue model requires ingredient and indication mapping plus cited market and financial data, neither of which is provided in a verifiable form for TARACTAN.

---

FAQs

1. Is TARACTAN an internationally recognized brand with published sales data?
   No source-backed, globally indexed sales and performance dataset can be produced for TARACTAN here.

2. What competition pressures does TARACTAN face?
   A verifiable competitive set cannot be constructed without validated active ingredient and indication mapping.

3. What drives TARACTAN’s pricing and reimbursement outcomes?
   Pricing and reimbursement determinants cannot be tied to TARACTAN without jurisdiction-specific, ingredient-indication identity.

4. How do patents and exclusivity affect TARACTAN’s revenue durability?
   A cited patent and exclusivity timeline cannot be generated without product-specific regulatory and patent mapping.

5. Can TARACTAN’s financial trajectory be inferred from corporate financials?
   Not without reliable segment attribution or cited product-specific revenue reporting that ties directly to TARACTAN.

---

References

[1] No cited sources were used because no verifiable TARACTAN product identity, regulatory listing, market performance, or financial reporting was available in the provided information.